Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M E Harper

Showing results (121-130 of 137) with videos related to

Pageof 14
Sort By:
The Journal of Biological Chemistry|December 8, 1995
Targeted disruption of the beta 3-adrenergic receptor geneV S Susulic, R C Frederich, J Lawitts, et al.
International Journal of Cancer|October 23, 2001
TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independenceE Glynne-Jones, M E Harper, L T Seery, et al.
The Journal of Steroid Biochemistry and Molecular Biology|April 30, 2005
Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategiesR I Nicholson, I R Hutcheson, D Britton, et al.
Endocrine-Related Cancer|September 22, 2001
Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancerR I Nicholson, I R Hutcheson, M E Harper, et al.
Diabetes|September 3, 1998
Mice expressing human but not murine beta3-adrenergic receptors under the control of human gene regulatory elementsM Ito, D Grujic, E D Abel, et al.
JAMA|November 7, 1986
Detection of HTLV-III RNA in lungs of patients with AIDS and pulmonary involvementK J Chayt, M E Harper, L M Marselle, et al.
Annals of the New York Academy of Sciences|July 4, 2002
Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancerR I Nicholson, I R Hutcheson, M E Harper, et al.
Nature|March 2, 1986
The trans-activator gene of HTLV-III is essential for virus replicationA G Fisher, M B Feinberg, S F Josephs, et al.
Endocrinology|September 10, 2003
The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitroJ M W Gee, M E Harper, I R Hutcheson, et al.
Nature|November 14, 1985
Multiple sclerosis and human T-cell lymphotropic retrovirusesH Koprowski, E C DeFreitas, M E Harper, et al.
Pageof 14

Showing results (121-130 of 137) with videos related to

Sort By:
Pageof 14
The Journal of Biological Chemistry|December 8, 1995
Targeted disruption of the beta 3-adrenergic receptor geneV S Susulic, R C Frederich, J Lawitts, et al.
International Journal of Cancer|October 23, 2001
TENB2, a proteoglycan identified in prostate cancer that is associated with disease progression and androgen independenceE Glynne-Jones, M E Harper, L T Seery, et al.
The Journal of Steroid Biochemistry and Molecular Biology|April 30, 2005
Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategiesR I Nicholson, I R Hutcheson, D Britton, et al.
Endocrine-Related Cancer|September 22, 2001
Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancerR I Nicholson, I R Hutcheson, M E Harper, et al.
Diabetes|September 3, 1998
Mice expressing human but not murine beta3-adrenergic receptors under the control of human gene regulatory elementsM Ito, D Grujic, E D Abel, et al.
JAMA|November 7, 1986
Detection of HTLV-III RNA in lungs of patients with AIDS and pulmonary involvementK J Chayt, M E Harper, L M Marselle, et al.
Annals of the New York Academy of Sciences|July 4, 2002
Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancerR I Nicholson, I R Hutcheson, M E Harper, et al.
Nature|March 2, 1986
The trans-activator gene of HTLV-III is essential for virus replicationA G Fisher, M B Feinberg, S F Josephs, et al.
Endocrinology|September 10, 2003
The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitroJ M W Gee, M E Harper, I R Hutcheson, et al.
Nature|November 14, 1985
Multiple sclerosis and human T-cell lymphotropic retrovirusesH Koprowski, E C DeFreitas, M E Harper, et al.
Pageof 14